

NOVO NORDISK A S  
Form 6-K  
October 01, 2014  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

October 1, 2014

---

NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

Novo Allé  
DK- 2880, Bagsvaerd  
Denmark  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

Status regarding Novo Nordisk's holding of its own shares (30 September 2014)

Bagsværd, Denmark, 1 October 2014 – In continuation of the company's announcements dated 30 January 2014 and 7 August 2014 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2014 owned 43,276,289 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 8,655,258 or 1.6% of the total share capital.

## Edgar Filing: NOVO NORDISK A S - Form 6-K

In the third quarter of 2014 a total of 15,213,000 B shares were repurchased, and 159,725 B shares were disposed of to employees in connection with employee incentive programmes.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).

### Further information

#### Media:

Anne Margrethe Hauge                      +45 4442 3450                      [amhg@novonordisk.com](mailto:amhg@novonordisk.com)

#### Investors:

Kasper Roseeuw Poulsen                      +45 3079 4303                      [krop@novonordisk.com](mailto:krop@novonordisk.com)  
Jannick Lindegaard Denholt                      +45 3079 8519                      [jlis@novonordisk.com](mailto:jlis@novonordisk.com)  
Daniel Bohsen                      +45 3079 6376                      [dabo@novonordisk.com](mailto:dabo@novonordisk.com)  
Frank Daniel Mersebach (US)                      +1 609 235 8567                      [fdni@novonordisk.com](mailto:fdni@novonordisk.com)

Novo Nordisk A/S  
Investor Relations

Novo Allé  
2880 Bagsværd  
Denmark

Telephone:  
+45 4444 8888

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)  
CVR no:  
24 25 67 90

Company announcement  
No 61 / 2014

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: October 1, 2014

NOVO NORDISK A/S

Lars Rebien Sørensen,  
Chief Executive Officer